



1 20 March 2024  
2 EMEA/HMPC/246816/2005 Rev. 1  
3 Committee on Herbal Medicinal Products (HMPC)

## Guideline on Good Agricultural and Collection Practice (GACP) for starting materials of herbal origin

Draft – Revision 1

Draft adopted by Committee on Herbal Medicinal Products (HMPC) for release for consultation	July 2005
End of consultation (deadline for comments)	30 October 2005
Draft agreed by HMPC Quality Drafting Group (QDG)	January 2006
Adoption by HMPC	12 January 2006
Date for coming into effect	1 August 2006
Draft Revision 1 agreed by HMPC QDG	05 December 2023
Draft Revision 1 agreed by Quality Working Party (QWP)	12 February 2024
Draft Revision 1 agreed by GMP/GDP Inspectors Working Group (GMDP IWG)	06 March 2024
Draft Revision 1 adopted by HMPC for release for consultation	20 March 2024
Start of public consultation	15 April 2024
End of consultation (deadline for comments)	15 July 2024

4  
5

Comments should be provided using this [template](#). The completed comments form should be sent to [hmpc.secretariat@ema.europa.eu](mailto:hmpc.secretariat@ema.europa.eu)

6  
7

Keywords	Committee on Herbal Medicinal Products; HMPC; herbal medicinal products; HMPs; traditional herbal medicinal products; THMPs; herbal substances; good agricultural and collection practice; GACP
----------	---

8  
9



10 **Table of contents**

11 Table of contents .....3

12 EXECUTIVE SUMMARY .....4

13 1. INTRODUCTION .....4

14 2. SCOPE.....4

15 3. QUALITY MANAGEMENT .....5

16 4. PERSONNEL AND TRAINING .....6

17 5. BUILDING AND FACILITIES .....7

18 6. EQUIPMENT .....7

19 7. DOCUMENTATION .....8

20 8. SEEDS AND PROPAGATION MATERIAL .....8

21 9. CULTIVATION .....9

22 10. COLLECTION .....10

23 11. HARVESTING .....10

24 12. PRIMARY PROCESSING .....11

25 13. PACKAGING .....12

26 14. STORAGE AND DISTRIBUTION .....13

27 15. DEFINITIONS .....13

28 16. REFERENCES .....14

29

## 30 EXECUTIVE SUMMARY

31 This guideline on Good Agricultural and Collection Practice (GACP) for starting materials of herbal origin  
32 came into effect in August 2006 and is intended to provide guidance to ensure appropriate and  
33 consistent quality of herbal substances<sup>1</sup>. The current Revision 1 of the GACP guideline pertains to an  
34 update of the document to current standards taking into account advances over the last 10 years, as  
35 for instance, the increased development of indoor growing technologies, and also cover the established  
36 practice and legal interpretations published during this period.

## 37 1. INTRODUCTION

38 Herbal medicinal plants can be collected from the wild or cultivated. In most cases cultivation is  
39 performed on the land, indoor cultivation or in greenhouses. Nowadays indoor cultivation, where  
40 environmental factors such as light, temperature, and humidity can be controlled, is increasingly  
41 applied.

42 The cultivation, production and primary processing of the medicinal plant-has a direct influence on the  
43 quality of the active pharmaceutical ingredient (API) used in herbal preparations<sup>2</sup>. Due to the inherent  
44 complexity of medicinal plants and herbal substances the quality of these starting materials requires an  
45 adequate quality assurance system for the collection and/or cultivation, harvest, and primary  
46 processing.

47 The choice of preferred conditions of obtention of the plants, for instance, wild collection or cultivation  
48 (either outdoor, indoor or in greenhouses) should be carefully considered, since each of the mentioned  
49 types could have several problems and advantages. The used cultivation method may be dependent on  
50 the final application of the herbal medicinal product. Collection in wild habitats for instance, may  
51 present special problems, especially with regard to confusion with similar plants, environmental  
52 damage, lack of control and poorly qualified personnel. Also, due to the possible non-uniformity  
53 between plants growing in the wild, variations in the composition can be a challenge exhibited by these  
54 plants. However, in situations where the agronomic requirements for a specific plant cannot be met by  
55 cultivation practices, manufacturers may opt for the collection of the specific herb from wild sources.  
56 This Guideline should be used as a basis for the establishment of an appropriate quality assurance  
57 system for the collection and/or cultivation, harvest and primary processing of herbal substances for  
58 use in the preparation of herbal medicinal products.

59 Information relating specifically to indoor cultivation is indicated in "*italics*".

## 60 2. SCOPE

61 This guideline is intended to address the specific concerns related to the cultivation, collection, and  
62 primary processing of herbal substances that are used for the preparation of herbal medicinal products.

63 It addresses specific issues associated with outdoor, greenhouse and indoor cultivation, collection of  
64 medicinal plants/herbal substances in the wild and production facilities for the primary processing of  
65 medicinal plants/herbal substances.

---

<sup>1</sup> The term "herbal substance" should be considered as equivalent to the term "herbal drug" as defined in the European Pharmacopoeia

<sup>2</sup> The term "herbal preparation" should be considered as equivalent to the term "herbal drug preparation" as defined in the European Pharmacopoeia

66 These considerations should be read in connection with [EudraLex Volume 4 GMP guidelines](#) Part II for  
67 APIs<sup>3</sup> and Annex 7<sup>4</sup> Manufacture of Herbal Medicinal Products and should apply to all methods of  
68 production in accordance with regional and/or national regulations.

69 The operations that should fall under the scope of GACP, GMP part II (for APIs) or GMP part I (for  
70 medicinal products) depend on the application of the finished medicinal product. In general, the closer  
71 the preparation is to the final product, the stricter the requirements are. For instance, the  
72 requirements applicable to a comminuted herbal substance sold as a herbal tea should be higher than  
73 the requirements applicable for a herbal substance which will be subject to further processing steps,  
74 such as extraction. Manufacturers should ensure that all the steps are carried out in accordance with  
75 the marketing authorisation/registration and therefore establish an appropriate quality assurance  
76 system in different cultivation circumstances. This Guideline provides additional standards for the  
77 production and processing of medicinal plants/herbal substances insofar as they mainly focus on  
78 identifying those critical production steps that are needed to ensure good quality.

79 The main aim is to ensure patient safety by establishing adequate quality standards for obtaining  
80 medicinal plants and herbal substances, ensuring that they are handled appropriately throughout all  
81 stages of cultivation, collection, processing and storage.

82 The handling of the herbal substance should be in accordance with good hygiene practices, to ensure  
83 microbiological load is kept to a minimum. Therefore, care should be taken avoid agricultural inputs  
84 e.g. fertilisers, growth media/promoters etc being a source of contamination.

85 During cultivation, harvest, collection, and primary processing, medicinal plants, herbal substances and  
86 their preparations are exposed to a large number of environmental contaminants of both biotic and  
87 abiotic origin. This Guideline provides recommendations for producers to reduce contamination to a  
88 minimum.

89 Considerations and recommendations in this Guideline are intended for all participants from cultivators,  
90 harvesters, collectors, producers, traders, and processors of medicinal plants and herbal substances.  
91 Therefore they each should comply with these considerations, document all relevant activities in batch  
92 documentation and demand that their partners do likewise, unless it can be justified. The manufacturer  
93 of medicinal product should ensure that regular audits of the primary producers (cultivators,  
94 harvesters, and collectors) are performed.

95 Growers and collectors of medicinal plants and herbal substances must ensure that they avoid damage  
96 to existing wildlife habitats and must adhere to CITES (Convention on International Trade in  
97 Endangered species of Wild Fauna and Flora).

### 98 **3. QUALITY MANAGEMENT**

99 Agreements between producers (cultivators, harvesters, collectors) and buyers of medicinal  
100 plants/herbal substances should make reference to the GACP quality assurance system and should be  
101 laid down in written form.

102 GACP quality assurance system compliance should be verified through regular audits of the cultivation  
103 or collection sites and processing facilities by expert representatives of producers and buyers.

---

<sup>3</sup> [https://health.ec.europa.eu/document/download/bd537ccf-9271-4230-bca1-2d8cb655fd83\\_en?filename=2014-08\\_gmp\\_part1.pdf](https://health.ec.europa.eu/document/download/bd537ccf-9271-4230-bca1-2d8cb655fd83_en?filename=2014-08_gmp_part1.pdf)

<sup>4</sup> [https://health.ec.europa.eu/document/download/fd318dd6-2404-4e67-82b0-2324825e4d90\\_en?filename=vol4\\_an7\\_2008\\_09\\_en.pdf](https://health.ec.europa.eu/document/download/fd318dd6-2404-4e67-82b0-2324825e4d90_en?filename=vol4_an7_2008_09_en.pdf)

## 104 **4. PERSONNEL AND TRAINING**

105 All primary processing procedures should fully conform with regional or national guidelines on hygiene  
106 and personnel entrusted with handling of medicinal plants/herbal substances. The personnel should be  
107 required to have a high degree of personal hygiene (including personnel working in the field) and have  
108 received adequate training regarding their hygiene responsibilities.

- 109 1. Personnel must be protected from contact with toxic or potentially allergenic medicinal  
110 plants/herbal substances via skin, eyes or inhalation, by means of adequate protective clothing  
111 or other adequate measures.
- 112 2. Persons suffering from known infectious transmittable diseases, must be suspended from areas  
113 where they are in contact with medicinal plants/herbal substances, according to regional  
114 and/or national regulations.
- 115 3. Persons with open wounds, inflammations and skin-infections should be suspended from areas  
116 where the plant processing takes place or should have to wear appropriate protective  
117 clothing/gloves until their complete recuperation. Special care should be applied when the  
118 herbal material is intended to be used in a further unprocessed state (irrespective to the route  
119 of administration).
- 120 4. There should be an adequate number of personnel qualified by appropriate education, training  
121 and/or experience to perform and supervise all related operations. Training should be regularly  
122 conducted by qualified individuals and should be periodically assessed. Records of training  
123 should be maintained, as required by the manufacturer.
- 124 5. Collectors must have sufficient knowledge of the plant they have to collect. This includes  
125 identification, characteristics and habitat requirements. The collectors must be able to  
126 differentiate between the collected species and botanically related and/or morphologically  
127 similar species to avoid any risk to public health and environmental damage. Collectors must  
128 have sufficient knowledge about the presentation of plant pests to recognize diseased  
129 plants/plant parts in order not to collect them. Collectors should have sufficient knowledge  
130 about the best time to harvest and harvesting technique, and the importance of primary  
131 processing to guarantee the best possible quality. Collectors should be instructed on all issues  
132 relevant to the protection of the environment and conservation of plant species, including  
133 information on regulations related to protected species. If collectors are lacking the adequate  
134 knowledge, a local supervisor should guarantee the training, supervision and documentation.
- 135 6. Personnel dealing with the medicinal plant and all those engaged in its cultivation should  
136 receive adequate botanical and agronomical training before performing particular cultivation  
137 steps (e.g., pruning) and regarding cultivation techniques, including appropriate use of  
138 herbicides and pesticides or beneficial arthropods and microorganisms. Personnel should  
139 receive adequate training in handling the plants (e.g., under controlled climate circumstances  
140 in case of indoor cultivation). Personnel must have sufficient knowledge about the presentation  
141 of plant pests to recognize diseased plants/plant parts in order not to harvest them. Harvesters  
142 should have sufficient knowledge about the best time to harvest and harvesting techniques and  
143 the importance of primary processing to guarantee the best possible quality.
- 144 7. Personnel should be trained in the maintenance and cleaning of equipment and schedules and  
145 procedures (including assignment of responsibility) should be established for the equipment  
146 maintenance and cleaning as a preventive measure against contamination.

147 8. In general, personnel should be trained not to engage in activities such as smoking, eating,  
148 drinking, eating and storing food in the direct proximity of the plants to avoid contamination.  
149 *For indoor cultivation these activities should be restricted to separate designated areas.*

## 150 **5. BUILDING AND FACILITIES**

151 Buildings used in the processing of harvested medicinal plants/herbal substances must be clean, as  
152 well as thoroughly aerated and must never be used for housing livestock.

153 Buildings must provide adequate protection for the harvested medicinal plants/herbal substances  
154 against birds, insects, rodents and domestic animals. In all storage and processing areas suitable pest  
155 control measures such as rodent traps, baits and electric insect killing machines must be operated and  
156 maintained by professionally qualified staff or contractors.

157 It is recommended that the packaged medicinal plant/herbal substance be stored:

- 158 • in buildings with concrete or similar easy to clean floors;
- 159 • on pallets;
- 160 • with a sufficient distance from the wall;
- 161 • well separated from other herbal substances to avoid cross-contamination.

162 Buildings where plant processing is carried out, must have changing facilities as well as toilets including  
163 hand-washing facilities, according to regional and/or national regulations.

164 *Indoor cultivation facilities should contain adequate systems for air, climate and humidity control, light,*  
165 *ventilation and air filtration systems. They are designed to:*

- 166 • *minimize potential contamination;*
- 167 • *facilitate cleaning, maintenance and other operations;*
- 168 • *be impermeable to cleaning and disinfecting agents.*

169 Designated areas for different stages of cultivation may be assigned.

## 170 **6. EQUIPMENT**

171 Equipment used in plant cultivation and processing should comply with the following points:

- 172 • Equipment should be clean, regularly serviced and maintained to ensure good working order  
173 and mounted, where applicable, in an easily accessible way. Furthermore, equipment used in  
174 fertiliser and pesticide application, or other operations must be qualified and regularly  
175 calibrated.
- 176 • Those machine parts that are in direct contact with the harvested medicinal plant, must be  
177 cleaned after use to ensure that remaining residue does not result in subsequent cross-  
178 contamination.
- 179 • The equipment should be made from appropriate materials so that cross-contamination of  
180 medicinal plants/herbal substances with chemicals and other non-desirable substances is  
181 prevented.

182 Equipment and other supportive systems used in the critical steps of cultivation, processing, packaging  
183 and storage, should be shown to be appropriate for the intended use, and this process should be  
184 documented.

## 185 **7. DOCUMENTATION**

186 The following should be documented as agreed with the manufacturer:

- 187 • All processes and procedures that may impact the quality of the product e.g. training, personal  
188 hygiene, cleaning and maintenance activities, irrigation, fertilisation, applications of pesticides  
189 and herbicides, harvesting, processing, packaging, residual plant material and management (if  
190 relevant).
- 191 • Any extraordinary circumstances occurring during the cultivation period that may influence the  
192 chemical composition of the medicinal plant, e.g., extreme weather conditions, pests and plant  
193 diseases (particularly in the harvest period).
- 194 • For cultivated medicinal plants: the geographical location i.e. exact country and region/ area/  
195 province. The type, quantity, and the date of harvest as well as the chemicals and other  
196 substances used during production. Site records showing previous crops, varieties and/ or  
197 cultivars and plant protection products used.
- 198 • For wild collection of medicinal plants: the geographic location i.e. exact country and region/  
199 area/ province. The type, quantity, and the date of collection.
- 200 • The use of fumigant products.
- 201 • Batches of herbal substances should be unambiguously and unmistakably traceable to their  
202 sources. Therefore, appropriate labelling and batch assignment should take place as early as  
203 possible in the process. Wild collected and cultivated material should be assigned different  
204 batch numbers.
- 205 • Single and combination batches of the same plant species harvested from different  
206 geographical location, i.e. exact country and region/ area/ province, and/ or subject to different  
207 cultivation conditions.
- 208 • All agreements between each producer or collector and the manufacturer, e.g., production  
209 guidelines, contracts etc. should be in written form.
- 210 • The audit reports, including those by or on behalf of the GMP licensed manufacturers or other  
211 parties. Copies of all documents, audit reports, analysis reports etc. should be stored.

212 *For indoor cultivation (and greenhouse, if applicable) the agronomic conditions and all materials*  
213 *used during cultivation should be fully documented. If applicable, acceptance criteria for all*  
214 *cultivation conditions to obtain the specified quality should be laid down and documented for each*  
215 *batch. All documents related to the cultivation and production should be prepared, reviewed,*  
216 *approved and distributed according to written procedures. A procedure should be established for*  
217 *retaining all appropriate documents. All the specifications related to the process and product should*  
218 *be documented. All cleaning activities should be recorded in the batch records and appropriate*  
219 *logbooks. For indoor cultivation daily records of critical process parameters must be kept and*  
220 *reviewed.*

## 221 **8. SEEDS AND PROPAGATION MATERIAL**

222 Seeds should originate from plants that have been accurately identified in terms of genus, species,  
223 variety/ cultivar/ chemotype and origin and should be traceable. The same applies to vegetatively  
224 propagated medicinal plants. Seeds and/ or vegetatively propagated medicinal plants used in organic  
225 production must be certified as organic. The starting material should be free from pests and diseases in  
226 order to guarantee healthy plant growth. Where possible, stable varieties and cultivars naturally

227 resistant or tolerant to disease should preferably be used. Seeds should be free from seeds of other  
228 species, especially seeds of plants that contain toxic components, like pyrrolizidine alkaloids.

229 The presence of different species, varieties, or different plant parts must be controlled during the entire  
230 production process, and such adulteration should be avoided. The use of genetically modified medicinal  
231 plants or seeds must comply with regional and/or national regulations.

232 Suppliers of materials used in cultivation must be evaluated and qualified according to established  
233 procedures. Changing the source of supply of materials should be handled through the Change Control  
234 procedure.

## 235 **9. CULTIVATION**

236 The chosen method of cultivation should be described in a standard operating procedure (SOP), taking  
237 care to avoid any negative environmental impact. The principles of good crop husbandry must be  
238 followed and include appropriate rotation of crops if applicable.

### 239 • Soil and fertilisation:

240 ○ Medicinal plants should not be grown in soil or substrate contaminated with sludge,  
241 heavy metals, residues, plant protection products or other chemicals. Any products  
242 used in the growth or protection of the crop should be kept to a minimum and its use  
243 should be justified.

244 ○ In cases where the area considered for the cultivation of the medicinal plant is  
245 potentially contaminated or is in close proximity to contaminated areas, the responsible  
246 person should take suitable measures (including testing) prior to the commencement of  
247 the cultivation process.

248 ○ Manure should be thoroughly composted and should be void of human faeces. The use  
249 of compost containing toxic plants must be avoided.

250 ○ All other fertilising agents should be applied sparingly and in accordance with the needs  
251 of the particular plant species. Fertilisers should be applied in such a manner as to  
252 minimise leaching.

253 ○ All fertilising agents should be appropriated in order to avoid contamination with heavy  
254 metals and organic contaminants, such as PCBs and PAHs.

### 255 • Irrigation:

256 ○ Irrigation should be controlled and carried out according to the needs of the medicinal  
257 plant.

258 ○ Water used in irrigation should comply with the country of destination's regional/  
259 national quality standards.

### 260 • Crop maintenance and plant protection:

261 ○ Tillage should be adapted to plant growth and requirements. During the cultivation  
262 season, any toxic weeds should be removed from the field and not composted.

263 ○ Pesticide and herbicide applications should be avoided as far as possible. When  
264 necessary, approved plant protection products should be applied at the minimum  
265 effective level in accordance with the recommendations from the manufacturer and  
266 approved by the authorities of the country of destination. Consideration should be  
267 given to exclude their application to those plants that rapidly uptake and retain them.



268 The application should be carried out only by qualified staff using approved equipment.  
269 The minimum interval between such treatment and harvest time must be stipulated by  
270 the buyer or be consistent with recommendations from the manufacturer of the plant  
271 protection product. Regional and/or national regulations on maximum residue limits in  
272 the European Pharmacopoeia, European Directives, Codex Alimentarius etc. should be  
273 complied with.

274 ○ In situations where the cultivation site is located in an area of other cultivation  
275 activities, the risk for possible contamination with pesticides and herbicides not  
276 approved for the concerned species should be assessed.

277 ○ The cultivated plant should be monitored for signs of defects, regardless of whether  
278 these are of biotic or abiotic origin. Suitable rogueing should be carried out to maintain  
279 the plant in good growing conditions.

280 ○ *In case of indoor cultivation (and if applicable to greenhouse setups), and if the*  
281 *following aspects should also be considered. There should be written procedures*  
282 *describing the receipt, identification, storage, handling, sampling and approval or*  
283 *rejection of materials. The company's overall policy, intentions, and approach to*  
284 *validation, including the validation of production processes, cleaning procedures and*  
285 *persons responsible for design, review, approval and documentation of each validation*  
286 *phase, should be documented. All the equipment involved in the cultivation process*  
287 *must be calibrated according to the established procedure and schedule. Before a new*  
288 *cultivation cycle, all materials used should be checked and approved by the person*  
289 *responsible for quality.*

290 ○ *For indoor cultivation critical quality attributes and critical process parameters should*  
291 *be identified. Appropriate in-process acceptance criteria and controls must be*  
292 *established. Cultivation process must be standardised in order to ensure reproducible*  
293 *results. Qualification of critical equipment and ancillary systems should be completed.*

## 294 **10. COLLECTION**

295 Designated individuals should supervise the collectors of the medicinal plants/herbal substances and  
296 also identify and verify the collected material (see 4.5, 4.6 and 4.7).

297 Collection must be carried out in compliance with existing regional and national and/or national species  
298 conservation legislation. Collection methods must not damage the growth environment ensuring  
299 optimum conditions for regeneration of the medicinal plant.

300 Medicinal plants/herbal substances from species that are listed as endangered (CITES, Convention on  
301 International Trade in Endangered Species of Wild Fauna and Flora) must not be collected unless the  
302 relevant competent authority has given its authorisation.

303 Medicinal plants/herbal substances from species that are not yet listed as endangered (section 10.3)  
304 should undergo a risk assessment prior to collection to ensure that the species is not pushed towards  
305 extinction.

## 306 **11. HARVESTING**

307 Medicinal plants/herbal substances should be harvested when they are at the best possible quality for  
308 the proposed use. The following should be noted:

- 309 • Damaged plants or plant parts need to be excluded or limited in accordance with a specific  
310 pharmacopoeia monograph, where relevant.
- 311 • Ensure the best possible conditions avoiding wet soil, dew, rain, or exceptionally high air  
312 humidity. Harvesting in wet conditions can have adverse effects on the medicinal plant/herbal  
313 substance. (e.g., postharvest spoilage).
- 314 • Cutting devices or harvesters must be appropriately cleaned and adjusted so that  
315 contamination from foreign matter, leaking lubricants, and other extraneous agents and/ or  
316 particles is reduced to a minimum. Such devices should always be maintained in good working  
317 order. Recommendations in section 6. Equipment must be followed and documented.
- 318 • The harvested medicinal plant/herbal substance should not come into direct contact with the  
319 soil or floor. It must be promptly collected in suitable containers and transported in dry, clean  
320 conditions.
- 321 • Care should be taken to ensure that no toxic weeds are co-harvested with medicinal  
322 plants/herbal substances.
- 323 • All containers used during harvesting must be clean and free of contamination from previous  
324 harvests. When containers are not in use, they must be kept in dry conditions free of pests and  
325 inaccessible to rodents, livestock and domestic animals.
- 326 • Mechanical damage and compacting of the harvested medicinal plant/herbal substance that  
327 would result in undesirable quality changes must be avoided. In this respect, attention must be  
328 paid to:
  - 329 ○ overfilling of the sacks;
  - 330 ○ stacking up of sacks.
- 331 • Freshly harvested medicinal plants/herbal substances must be delivered as quickly as possible  
332 to the processing facility to prevent physical or chemical degradation or microbial growth.
- 333 • The harvested crop must be protected from pests, rodents, livestock and domestic animals.  
334 Any pest control measures taken must be documented.

## 335 **12. PRIMARY PROCESSING**

336 Primary processing may include washing, cutting before drying, microbial decontamination, freezing,  
337 distillation, primary and secondary drying, etc. Where applicable, all these processes must conform to  
338 the competent authority regulations and should be carried out as soon as possible after harvesting.

339 In some circumstances drying and cutting should be performed according to [EudraLex Volume 4](#) GMP  
340 part I or II (refer the GMP Table<sup>5</sup> in Annex 7).

341 In exceptional circumstances, which must be justified in the marketing authorisation/registration, some  
342 of these steps, like expression and distillation, may be performed in the field, only if it is necessary for  
343 these activities to be an integral part of harvesting in order to maintain the quality of the product  
344 within the approved specification (see note to the Table of GMP Annex 7).

- 345 • On arrival at the processing facility, the harvested medicinal plant/herbal substance must be  
346 promptly unloaded and unpacked. Prior to processing, the material should not be exposed

---

<sup>5</sup> The Table illustrating the application of Good Practices to the manufacture of herbal medicinal products is found in EudraLex Vol. 4 Annex 7, page 3.

347 directly to the sun (except in cases where there is a specific need) and must be protected from  
348 rainfall, insect infestation, etc.

- 349 • In the case of natural open-air drying, the medicinal plant/herbal substance must be spread  
350 out in a thin layer. To secure adequate air circulation, the drying frames must be located at a  
351 sufficient distance from the ground. Drying directly on the ground or under direct exposure to  
352 the sunlight should be avoided unless specifically required. Attempts must be made to achieve  
353 uniform drying of the medicinal plant/herbal substance and thus avoid mould formation and to  
354 maintain quality.
- 355 • The drying conditions such as maximum temperature, duration and air circulation must be  
356 selected taking into consideration the medicinal plant part to be dried, such as root, leaf or  
357 flower, and the nature of its active constituent, such as essential oils. Individual conditions  
358 must be recorded in detail. In case of artificial drying, gas or electrical ovens should be  
359 considered, and the use of wood and petrol ovens minimised, to reduce to possible  
360 contamination with polycyclic aromatic hydrocarbons (PAHs).
- 361 • In case of distillation in the field (refer the GMP Table<sup>5</sup> in Annex 7), this can be performed at a  
362 small plant in the field, which should be audited by the finished product manufacturer and  
363 validated according to GMP principles, and may be subject to inspections by Regulatory  
364 Authorities to assess compliance.
- 365 • All materials must be inspected and where necessary sieved to eliminate sub-standard product  
366 and foreign matters. Sieves must be maintained in a clean state and should be serviced  
367 regularly.
- 368 • Clearly marked waste-bins should be available, emptied daily and cleaned. The waste plant  
369 material must be segregated from growing media and the materials for the cultivation of  
370 plants. The waste plant material may require incineration for destruction.
- 371 • Fumigation should be limited as far as possible and only be used when a real need is identified.  
372 In such cases, treatment should be carried out at the earliest possible stage, according to the  
373 specific recommendations for use<sup>6</sup>.
- 374 • Fumigation against pest attack should be carried out only where necessary and must be carried  
375 out exclusively by licensed personnel. Only registered chemicals must be used. The use of  
376 ethylene oxide and 1,3-dichloropropene is prohibited. Any fumigation against pests must be  
377 documented (see section 7).
- 378 • For fumigation of warehouses, only substances permitted by the regional and/or national  
379 regulations should be used and documented (see section 7).
- 380 • When frozen storage or saturated steam is used for pests and microbial contamination control,  
381 the humidity of the material must be controlled after treatment.

## 382 **13. PACKAGING**

383 To protect the product and to reduce the risk of pest attacks, early packaging is advisable.

384 Following processing monitored by in-process controls, the product should be packaged in clean and  
385 dry, preferably new sacks, bags or cases. The label must be clear, permanently fixed and made from

---

<sup>6</sup> Reflection paper on the use of fumigants (EMA/HMPC/125562/2006)

386 non-toxic material. Information must conform with regional and/or labelling regulations of the country  
387 of destination.

388 Reusable packaging material should be well cleaned and properly dried prior to use. No contamination  
389 should occur through reusing of bags.

390 Packaging materials must be stored in a clean and dry place that is free of pests and inaccessible to  
391 livestock and domestic animals. It must be guaranteed that the packaging materials do not cause  
392 contamination of the product, particularly in the case of fibre bags.

## 393 **14. STORAGE AND DISTRIBUTION**

394 Packaged dried medicinal plants/herbal substances and essential oils, should be stored in a dry, well-  
395 aerated building, in which daily temperature fluctuations are defined and limited and good ventilation is  
396 ensured.

397 In the case of bulk transport, it is important to secure dry conditions. Furthermore, to reduce the risk  
398 of mould formation or fermentation it is advisable to use aerated containers. As a substitute, the use of  
399 sufficiently aerated transport vehicles and other aerated facilities is recommended. Essential oil  
400 transport must conform with appropriate regulations. Regional and/ or national regulations on  
401 transport must be respected.

## 402 **15. DEFINITIONS**

403 Abiotic: Physical instead of biological factors or compounds. Examples are sunlight,  
404 water, air, type of soil, minerals, etc.

405 Adulteration: The illegal and fraudulent mixing of ingredients that are not declared.

406 Agricultural inputs: Any incoming material (e.g. seeds, fertilizers, including compost, water,  
407 agricultural chemicals, plant support) used for the primary production of  
408 herbal substances.

409 Biotic: Relating to living organisms.

410 CITES: Convention on International Trade in Endangered species of Wild Fauna and  
411 Flora.

412 Collection: The gathering of plant species from wild/spontaneous sources.

413 Fumigation: The process of disinfecting a batch in a closed container with the fumes of  
414 certain chemicals.

415 Greenhouse: A facility designed for the cultivation of plants under automated and/or  
416 manually semi-controlled climate conditions. They can be of glass or other  
417 light transparent materials. They can be open and in contact with the  
418 external environment if needed, depending on the internal/external climate  
419 conditions.

420 Habitat: The natural home or environment of a plant species.

421 Harvesting: The gathering of plant species from cultivated sources.

422 Herbal substances: Are mainly whole, fragmented or cut, plants, parts of plants, algae, fungi,  
423 lichen in an unprocessed state, usually in dried form but sometimes fresh.  
424 Certain exudates that have not been subjected to a specific treatment are

425		also considered to be herbal substances. Herbal substances are precisely
426		defined by the plant part used and the botanical name according to the
427		binominal system (genus, species, variety and author).
428	Herbal preparations:	Are obtained by subjecting herbal substances to treatments such as
429		extraction, distillation, expression, fractionation, purification, concentration
430		or fermentation. These include comminuted or powdered herbal substances,
431		tinctures, extracts, essential oils, expressed juices and processed exudates.
432	Indoor cultivation:	Cultivation in a closed environment equipped with air filtration to avoid
433		cross-pollination, pollutants, insects etc.
434	Outdoor cultivation:	Live plants growing in an area (open field) exposed to natural sunlight and
435		environmental conditions including variable temperature, precipitation, and
436		wind.
437	Olfactory:	Relating to the sense of smell.
438	Organic production:	A sustainable agricultural system that uses ecologically based pest controls
439		and biological fertilizers derived largely from animal and plant wastes and
440		nitrogen-fixing cover crops. For further information see Regulation (EU)
441		2018/848.
442	Postharvest spoilage:	The presence of moulds and other organisms that may impact negatively on
443		the quality of the herbal material.
444	Pyrrrolizidine alkaloids:	PAs are a group of naturally occurring alkaloids in certain plants that are
445		based on the structure of pyrrrolizidine that are toxic to the liver.
446	Residual plant materials:	Are crop materials such as stems, leaves, and roots, that are left on the field
447		after the harvest. There are different ways to manage crop residues. They
448		can be used for tillage prior to planting when plant residues are incorporated
449		into the soil. Another farming practice is reduced tillage or no-till farming,
450		where crop residues are left on the surface and planting is carried out
451		without soil tillage. The residues can also be used for composting and, in
452		some cases, like Cannabis, they need to be destroyed.
453	Rogue/rogueing:	The removal of inferior or defective plants or seedlings from a crop.
454	Tillage:	Agricultural preparation of the soil by mechanical agitation in preparation for
455		growing crops.

## 456 **16. REFERENCES**

- 457 1. EudraLex Volume 4 Part II "Basic Requirements for Active Substances used as Starting Materials".  
458 Good Manufacturing Practices (GMP) for medicinal products, Volume 4, The rules governing medicinal  
459 products in the European Union, current version
- 460 2. EudraLex Volume 4 Annex 7 "Manufacture of herbal medicinal products" of Good Manufacturing  
461 Practices (GMP) for medicinal products, Volume 4, The rules governing medicinal products in the  
462 European Union, current version
- 463 3. European Pharmacopoeia General Monograph "HERBAL DRUGS" 07/2017:1433

- 464 4. Reflection paper on the use of fumigants (EMA/HMPC/125562/2006)
- 465 5. Reflection paper on quality of essential oils as active substances in herbal medicinal  
466 products/traditional herbal medicinal products (EMA/HMPC/84789/2013)
- 467 6. REGULATION (EU) 2018/848 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 30 May  
468 2018 on organic production and labelling of organic products and repealing Council Regulation (EC) No  
469 834/2007